Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology and Co-Lead Thoracic Site Disease Group, Associate Director of Community Outreach at Sylvester Comprehensive Cancer Center, shared a post on X by Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Irelan, adding:
“Truly exciting times for SCLC therapies – being able to offer BiTES and ADCs with CNS activity is a gamechanger (except the toxicity of these agents is real and requires patient selection).”
Quoting Jarushka Naidoo‘s post:
“CNS activity in BiTES and ADCs
Excellent talk from Bingnan Zhang, MD Anderson Cancer Center on intracranial response of untreated BM from tarlatamab in SCLC:
– 10 patients (9 BM, 1 LMD)
– icORR 90%
– selected responses rapid
Can we avoid WBRT in these patients?”
More posts featuring Estela Rodriguez and Jarushka Naidoo on OncoDaily.
